FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease

The FDA approved zilganersen (Zanvastro) as the first disease-modifying treatment for Alexander disease, based on data showing improved gait speed and motor function in pediatric and adult patients. The approval includes patients from infancy through adulthood and requires intrathecal dosing every 12 weeks, with monitoring for aseptic meningitis and other side effects.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.